You are here: Industry Insights > GenScript Biotech

News List

cPass(TM) SARS-CoV-2 Neutralization Antibody kit is the first EUA authorized test that detects neutralizing antibodies within one hour prnasia
November 11, 2020
Following GenScript Biotech Corporation's cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit has received provisional authorization by Health Science Authority (HSA) Singapore on 8th May 2020, CE-IVD marking in Europe on 26th May 2020 and FDA ...
Beroni Signs Agreement with CDMO Genscript Biotech contractpharma
August 13, 2020
To conduct further study to develop nanobody-based medical solution for COVID-19.
GenScript Files for EUA of Rapid SARS-CoV-2 Neutralization Antibody Detection Kit americanpharmaceuticalreview
June 15, 2020
GenScript Biotech announced the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.
GenScript ProBio, Eutilex Enter Cancer Collaboration contractpharma
April 10, 2020
Partner on plasmid and virus process development and manufacturing for CAR-T programs.
GenScript Biotech starts operations for Biologics R&D and production center biospectrumasia
July 20, 2019
Biologics commercial production centre will be the first and largest such facility in China covering cell therapy, gene therapy and antibody-drug R&D to meet the production needs of pre-clinical and phase I clinical samples